Myriad Genetics (MYGN) Expected to Announce Quarterly Earnings on Tuesday

Myriad Genetics (NASDAQ:MYGN) will likely be announcing its earnings results before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of $0.03 per share and revenue of $210.35 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Myriad Genetics Price Performance

MYGN opened at $14.19 on Friday. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -10.92 and a beta of 1.88. Myriad Genetics has a fifty-two week low of $12.04 and a fifty-two week high of $29.30. The company’s 50-day moving average price is $13.45 and its 200 day moving average price is $19.53. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Leerink Partners lowered shares of Myriad Genetics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $30.00 to $21.00 in a research note on Monday, December 9th. Bank of America dropped their price objective on shares of Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating on the stock in a research note on Friday, December 13th. The Goldman Sachs Group dropped their price objective on shares of Myriad Genetics from $29.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Craig Hallum assumed coverage on shares of Myriad Genetics in a research note on Wednesday, February 12th. They set a “buy” rating and a $29.00 price objective on the stock. Finally, UBS Group initiated coverage on shares of Myriad Genetics in a research note on Tuesday, December 10th. They set a “neutral” rating and a $18.00 price objective on the stock. Three analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $22.54.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.